Shopping Cart
Remove All
Your shopping cart is currently empty
Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 5 mg | $73 | In Stock | In Stock | |
| 10 mg | $118 | In Stock | In Stock | |
| 25 mg | $238 | In Stock | In Stock | |
| 50 mg | $355 | In Stock | In Stock | |
| 100 mg | $507 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $81 | In Stock | In Stock |
| Description | Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7. |
| Targets&IC50 | TLR8:100 nM(EC50) |
| In vitro | Motolimodinduces the production of both TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs. In mDCs and monocytes, Motolimodspecifically induces the production of IL-12 and TNFα via NF-κB activation. Motolimodalso induces IFNγ production from NK cells, enhances the lytic function of NK cells and augments ADCC. |
| In vivo | In ovarian cancer mouse model, TX-2337 augments the effect of pegylated liposomal doxorubicin (PLD). |
| Kinase Assay | The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out. |
| Cell Research | PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell-mediated cytotoxicity is assessed by Calcein-AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells. |
| Synonyms | VTX-378, VTX-2337 |
| Molecular Weight | 458.6 |
| Formula | C28H34N4O2 |
| Cas No. | 926927-61-9 |
| Smiles | CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |
| Relative Density. | 1.19 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 12 mg/mL (26.17 mM), Sonication is recommended. DMSO: 51 mg/mL (111.21 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.36 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.